US6700024010 - Common Stock
4.6 +0.62 (+15.58%)
DoorDash stock is rising higher on Thursday after Morgan Stanley upgraded DASH shares and increased their price target for them.
Rivian stock is falling hard on Friday as RIVN investors react to a warning from Morgan Stanley and a weak EV production guidance for 2024.
Thursday's session: gap up and gap down stocks
Novavax stock is climbing higher on Thursday as investors in NVAX shares react to it reaching a $475 million settlement with Gavi.
Novavax (NVAX) agrees to refund Gavi at least $475M in cash or vaccines to settle a dispute over a COVID-19 vaccine purchase agreement.
Bull markets usually favor stocks with promising growth prospects.
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) and Gavi, the Vaccine Alliance (Gavi) today announced they have reached a settlement related to the 2021 Advance...
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its...
Although these market ideas are extremely speculative, their upcoming catalysts could make them stocks to buy now.
Without any windfalls on the horizon, times are dire for this biotech.
Spot the looming risks in the biotech sector and avoid these three doomed biotech stocks likely to burn shareholder value significantly.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips The unpredictable nature of the biotech industry, which frequently flirts with ...
Bull markets favor growth stocks so now could be the time for these players to shine.
Both stocks have fallen more than 90% from their peak.
A malaria vaccine based on technology from Novavax (NVAX) shows promising results with a 75% efficacy rate in African children. Read more here.
Novavax aims to win with its coronavirus/flu vaccine candidate, now in clinical trials.
The Novavax layoffs are coming for 12% of the company's global workforce. However, NVAX stock itself could shock the market.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotechnology firm Novavax (NASDAQ:NVAX)– which specializes in developing...
Novavax (NVAX) plans to cut 12% of its workforce to reduce expenses amid lower demand for COVID-19 products. Read more here.
If a trio of Wall Street analysts is correct, three lesser-known stocks could skyrocket in the new year.
This biotech isn't at the end of the road just yet, but don't bet on a revival.
The stock is high risk, but rewards could be great if all works out well for Novavax.
The biotech could fade into irrelevance soon.
Can the beaten-down stock turn things around?
Novavax faces a couple of key issues that could be crucial for the stock price.
Be sure to sell these meme stocks as they represent fundamentally weak businesses that will continue to erode in value.
Sometimes buying stocks at a 52-week low is a chance to buy a good company at great prices but you need to see if the business is busted.
High-water price targets from select analysts imply triple-digit gains in the new year for three former highfliers.
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will...
Biotech stocks gain as Bank of America takes a more positive view on SMID-cap stocks and specialty pharma. Read more here.